Nasdaq · Healthcare
Ceribell, Inc. (CBLL)
As-reported financials and recent SEC filings for Ceribell, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$89.1M
Net income
$-53.4M
Net margin
-60.0%
Diluted EPS
$-1.46
ROE
-34.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 |
|---|---|---|---|
| Revenue | $89.1M | $65.4M | $45.2M |
| Gross profit | $78.3M | $56.8M | $38.2M |
| Operating income | $-58.4M | $-39.7M | $-30.0M |
| Net income | $-53.4M | $-40.5M | $-29.5M |
| Diluted EPS | $-1.46 | $-1.13 | $-0.93 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-15
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-10
View on EDGAR →1442026-06-08
View on EDGAR →42026-06-04
View on EDGAR →Largest Healthcare peers
Go deeper on CBLL
Search Ceribell, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.